Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777
Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the cutaneous T-cell lymphoma indication approval and up to $70 million for additional indication approvals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2021 Category: Pharmaceuticals Source Type: news
Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics Mycosis Fungoides Hospitalizations Longer for Blacks, Hispanics
Results are consistent with prior studies that have found Black and Hispanic patients have earlier and more severe disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
Moffitt researchers discover potential new drug target to treat cutaneous T cell lymphoma
(H. Lee Moffitt Cancer Center& Research Institute) In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of Moffitt scientists conducted a series of studies. In an article published in The Journal of Clinical Investigation, they demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news
Extracoporeal photophoresis cost effective in cutaneous T-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2020 Category: Drugs & Pharmacology Source Type: news
Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy
Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold
Reinforces positive SGX301 prima... Biopharmaceuticals, Oncology Soligenix, synthetic hypericin, cutaneous T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2020 Category: Pharmaceuticals Source Type: news
Discovery could lead to new treatment for rare blood disease
(University of Alberta Faculty of Medicine& Dentistry) A new study shows cancer cells found in the lesions on the skin of cutaneous T-cell lymphoma patients originate from the blood, not the skin as was believed. The protocol to treat the disease was to eliminate the cancer cells from the skin. Based on the findings, researchers believe it would be more effective to treat the malignant clones in the blood rather than waiting until the cells reach the skin and present as lesions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news
Hodgkin and CTCL May Share a Gene Fusion and T-Cell Clone Hodgkin and CTCL May Share a Gene Fusion and T-Cell Clone
Genomic profiling may help diagnose Hodgkin lymphoma in patients who exhibit signs of an associated CTCL but lack B-lineage markers.JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome HSCT in Advanced Stage Mycosis Fungoides and Sezary Syndrome
Is HSCT potentially curative for cutaneous T-cell lymphoma?Chinese Clinical Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Journal Article Source Type: news
Skin Care Guidelines for Patients With Mycosis Fungoides Skin Care Guidelines for Patients With Mycosis Fungoides
Optimal cleansers, moisturizers, and bathing habits are reviewed in these skin care guidelines for patients with cutaneous lymphoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides Low-dose, Low-frequency PUVA May Be Suitable for Maintenance Therapy in Mycosis Fungoides
In patients with early-stage mycosis fungoides, treatment and maintenance therapy with low-dose, low-frequency oral psoralen - UV-A (PUVA) may extend disease-free remission, a proof-of-concept study reveals.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 27, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
City of Hope awarded $7.5 million to develop better treatment for a rare, incurable cancer
(City of Hope) City of Hope recently received $7.5 million to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma. The NCI awarded $6.3 million over five years to City of Hope's Steven Rosen, M.D., and Christiane Querfeld, M.D., Ph.D., so they can develop improved therapies for the disfiguring, incurable cancer that affects about 3,000 new individuals per year. LLS gave the pair two grants totaling $1.2 million over three years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2019 Category: International Medicine & Public Health Source Type: news
Book Review: Living Light: The Art of Using Light for Health & Happiness
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light.
“It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg.
In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better.
Light, we know, plays an important role in seasona...
Source: Psych Central - March 10, 2019 Category: Psychiatry Authors: Claire Nana Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news
Antibody-Based Therapies for Cutaneous T-Cell Lymphoma Antibody-Based Therapies for Cutaneous T-Cell Lymphoma
Monoclonal antibody therapies, such as alemtuzumab, brentuximab vedotin, and mogamulizumab, are showing promise for previously relapsed and refractory CTCL.American Journal of Clinical Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Traci DeVito Source Type: news
